The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act.
June 17, 2021
|
3 min read
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
June 16, 2021
|
2 min read
The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.
June 9, 2021
|
4 min read
The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.
April 15, 2021
|
2 min read